Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.
Applications
Suitable for use in FLISA, Immunohistochemistry and Immunofluorescence. Other applications not tested.
Recommended Dilution
Optimal dilutions to be determined by the researcher.
Storage and Stability
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Note: Applications are based on unconjugated antibody.
Immunogen
Purified recombinant EBNA-1.
Form
Supplied as a liquid in PBS, pH 7.2. No preservative added. No stabilizing proteins added. Labeled with Fluorescein isothiocyanate (FITC).
Purity
Purified IgG fraction to a purity of >95%.
Specificity
Recognizes Epstein-Barr nuclear antigen. Non-reactive with human lymphoid cells. Functions in ELISA against various recombinant EBNA-1 preps.